Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 2
1970 1
1972 1
1973 1
1974 4
1975 14
1976 10
1977 19
1978 10
1979 12
1980 18
1981 22
1982 23
1983 17
1984 24
1985 26
1986 29
1987 34
1988 26
1989 30
1990 21
1991 29
1992 28
1993 19
1994 24
1995 30
1996 28
1997 29
1998 19
1999 15
2000 24
2001 17
2002 15
2003 18
2004 15
2005 12
2006 22
2007 6
2008 11
2009 10
2010 14
2011 17
2012 17
2013 24
2014 19
2015 18
2016 12
2017 9
2018 14
2019 18
2020 17
2021 18
2022 21
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

900 results
Results by year
Filters applied: . Clear all
Page 1
Low-dose methotrexate toxicity.
Pivovarov K, Zipursky JS. Pivovarov K, et al. CMAJ. 2019 Apr 15;191(15):E423. doi: 10.1503/cmaj.181054. CMAJ. 2019. PMID: 30988043 Free PMC article. No abstract available.
Amelioration of Bleomycin and Methotrexate-Induced Pulmonary Toxicity by Serratiopeptidase and Fisetin.
Shahbaz M, Kamran SH, Anwar R. Shahbaz M, et al. Nutr Cancer. 2021;73(11-12):2774-2784. doi: 10.1080/01635581.2020.1860242. Epub 2020 Dec 23. Nutr Cancer. 2021. PMID: 33353415
Pulmonary toxicity by anticancer drugs often leads to discontinuation of therapy or switching the therapy to alternative drugs. ...SPTD and NAC showed significant (p < 0.05) effect in BLM-induced pulmonary toxicity by increasing GSH and decreasing M
Pulmonary toxicity by anticancer drugs often leads to discontinuation of therapy or switching the therapy to alternative drugs
Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics.
Li S, Shi J, Tang H. Li S, et al. Cell Biol Toxicol. 2022 Oct;38(5):699-723. doi: 10.1007/s10565-021-09676-z. Epub 2021 Nov 5. Cell Biol Toxicol. 2022. PMID: 34741237 Review.
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by progressive loss of pulmonary function. Drug-induced interstitial lung disease has been reported as a severe adverse effect of some drugs, such as bleomycin …
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by progressive loss of pulmona
Methotrexate Pulmonary Toxicity: Deep Inspiration.
Kremer JM. Kremer JM. Arthritis Rheumatol. 2020 Dec;72(12):1959-1962. doi: 10.1002/art.41451. Epub 2020 Oct 8. Arthritis Rheumatol. 2020. PMID: 32720443 No abstract available.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Bolaños-Meade J, et al. Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7. Lancet Haematol. 2019. PMID: 30824040 Free PMC article. Clinical Trial.
Compared with controls, the hazard ratio for GRFS was 0.72 (90% CI 0.54-0.94; p=0.044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0.98 (0.76-1.27; p=0.92) for tacrolimus, methotrexate, and bortezomib, and 1.10 (0.86-1.41; p=0.49) for …
Compared with controls, the hazard ratio for GRFS was 0.72 (90% CI 0.54-0.94; p=0.044) for tacrolimus, mycophenolate mofetil, and post-trans …
Methotrexate pulmonary toxicity.
Lateef O, Shakoor N, Balk RA. Lateef O, et al. Expert Opin Drug Saf. 2005 Jul;4(4):723-30. doi: 10.1517/14740338.4.4.723. Expert Opin Drug Saf. 2005. PMID: 16011450 Review.
Pulmonary infiltrates are the most commonly encountered form of methotrexate pulmonary toxicity and these infiltrates resemble hypersensitivity lung disease. This discussion focuses primarily on low-dose methotrexate pulmonary t
Pulmonary infiltrates are the most commonly encountered form of methotrexate pulmonary toxicity and these infilt
Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review.
Rondon F, Mendez O, Spinel N, Ochoa C, Saavedra C, Penaranda E, Garcia-Valladares I, Espinoza LR, Iglesias-Gamarra A. Rondon F, et al. Clin Rheumatol. 2011 Oct;30(10):1379-84. doi: 10.1007/s10067-011-1765-7. Epub 2011 May 26. Clin Rheumatol. 2011. PMID: 21614476 Review.
Patient, though, died despite immediate discontinuation of methotrexate and initiation of treatment with IV methylprednisolone and cyclophosphamide. Post-mortem examination showed diffuse interstitial pulmonary fibrosis. Methotrexate-induced pulmonary
Patient, though, died despite immediate discontinuation of methotrexate and initiation of treatment with IV methylprednisolone and cy …
Methotrexate pulmonary toxicity.
Cannon GW. Cannon GW. Rheum Dis Clin North Am. 1997 Nov;23(4):917-37. doi: 10.1016/s0889-857x(05)70366-5. Rheum Dis Clin North Am. 1997. PMID: 9361161 Review.
The characteristic symptoms are shortness of breath, nonproductive cough, fatigue, and fever. If an MTX-induced pulmonary reaction is suspected and abnormalities are noted on lung examination, chest radiography should be performed. ...No risk factors have been ident …
The characteristic symptoms are shortness of breath, nonproductive cough, fatigue, and fever. If an MTX-induced pulmonary reaction is …
Mechanisms underlying methotrexate-induced pulmonary toxicity.
Kim YJ, Song M, Ryu JC. Kim YJ, et al. Expert Opin Drug Saf. 2009 Jul;8(4):451-8. doi: 10.1517/14740330903066734. Expert Opin Drug Saf. 2009. PMID: 19538103 Review.
However, MTX-induced pulmonary toxicity is a serious and unpredictable side effect of the therapy, which includes allergic, cytotoxic or immunologic reactions, and is a major clinical problem. OBJECTIVE: To summarize the mechanisms of action involved in MTX-induced …
However, MTX-induced pulmonary toxicity is a serious and unpredictable side effect of the therapy, which includes allergic, cy …
Methotrexate-induced pulmonary toxicity.
Jakubovic BD, Donovan A, Webster PM, Shear NH. Jakubovic BD, et al. Can Respir J. 2013 May-Jun;20(3):153-5. doi: 10.1155/2013/527912. Can Respir J. 2013. PMID: 23762881 Free PMC article.
Methotrexate is a widely used medication with an array of recognized side effects. The present report describes a case of methotrexate-induced pneumonitis in a patient with psoriasis, and demonstrates the hallmark clinical and investigational findings that support t
Methotrexate is a widely used medication with an array of recognized side effects. The present report describes a case of methotre
900 results